cyrilzakka/clinical-trials huggingface dataset:
Motion Capture: Baseball Swing

The aim of this study will be to assess kinetic and kinematic data during different phases of baseball hitting progressions commonly employed in the rehabilitation setting.

Study participants will undergo consent and history process. Subjects must meet inclusion and exclusion criteria prior to consent. Once consent is obtained, each subject will undergo instruction and training expectations of each swing phase. Once an adequate determination of proficiency has been met, each subject will undergo EMG and MOTUS sleeve placement on each upper extremity:

* Forearm flexors
* Forearm extensors
* Medial epicondyle
* Lateral epicondyle
* Posterior rotator cuff musculature

Once participants have undergone appropriate calibration processes, they will perform listed swing progressions in a randomized order:

A. Dry swings - reduced weight (wiffleball) bat - 5 swings light intensity (25-50% effort), 5 swings moderate intensity (50-75% effort), 5 swings high intensity (75-100% effort) B. Dry swings - normal weight bat - 5 swings light intensity (25-50% effort), 5 swings moderate intensity (50-75% effort), 5 swings high intensity (75-100% effort) C. Tee hitting - normal weight bat - middle strike zone level - 5 swings light intensity (25-50% effort), 5 swings moderate intensity (50-75% effort), 5 swings high intensity (75-100% effort) D. Soft toss - underhand toss from assistant - middle strike zone placement - 5 swings light intensity (25-50% effort), 5 swings moderate intensity (50-75% effort), 5 swings high intensity (75-100% effort) E. Simulated hitting - pitching machine - randomized strike zone placement - 5 swings light intensity (25-50% effort), 5 swings moderate intensity (50-75% effort), 5 swings high intensity (75-100% effort)

Eligibility Criteria:
Inclusion Criteria:

* Participants must be healthy volunteers who accept all provisions of the study and agree to complete the program in its entirety. Participants should have their own bat and relative experience of at least 2 years of hitting a baseball. Ages accepted will be 16-40.

Exclusion Criteria:

1. Previous history of upper extremity injury
2. Current painful dysfunction resulting in exercise or participation limitation
3. Any health-related exercise limitation as ordered by physician
4. Ages outside of 16-40
5. Inability to access clinic and equipment
6. Inexperience with baseball hitting or inability to follow instructions from study staff.
Prospective Pilot Study ANDPrecise

This study aims at providing first evidence that axillary clearance by using an operation technique including the precise LigaSure instrument and closure of dead space of the axilla will result in an operation were a drain is not necessary and the need for seroma evacuation after surgery is very limited.

Axillary clearance in breast cancer is usually performed by using a drain to prevent seroma formation and to support obliteration of the dead space in the axillary carry out. The hypothesis made in this protocol is that axillary clearance by using an operation technique including the use of the precise LigaSure instrument and closure of dead space can be done without using a postoperative drain.

The AND PRECISE PROTOCOL aims at providing first evidence that axillary clearance by using an operation technique including the precise LigaSure instrument and closure of dead space of the axilla will result in an operation were a drain is not necessary and the need for seroma evacuation after surgery is very limited Patients undergoing axillary clearance necessary for achieving reasonable control in invasive breast cancer and participating in the AND PRECISE protocol will undergo the operation by using a technique including the use of the precise LigaSure instrument and closure of dead space. Postoperatively, the numbers of seroma punctions and the amount of seroma will be recorded prospectively. Patients will be asked to record on a daily basis their experience of pain by a visual analog scale of pain.

The main study parameter is the percent of cases which successfully did not need seroma punctions after the intervention.

Potential disadvantages for the patient are risk for more seroma formation and discomfort. Patients will be asked to record on a daily basis their experience of pain by a visual analog scale of pain.

Eligibility Criteria:
Inclusion Criteria:

* Indications for axillary clearance can be a tumor positive sentinel node or tumor positive lymph nodes proven by ultrasound or fine needle aspiration cytology.
* For this pilot, only patients undergoing breast conserving surgery are eligible.
* Axillary clearance can be performed after previous sentinel node procedure, at the same operation, and after neo-adjuvant chemo therapy, and as secondary procedure in case of axillary relapse after previous treatment for breast cancer.

Exclusion Criteria:

* Patients undergoing a modified radical mastectomy including an axillary clearance.
* Preoperative preexisting seroma.
Glucose Levels in Early Pregnancy and Feto-maternal Outcome

to find out whether variations in the fasting blood glucose in early pregnancy affect the fetomaternal outcome

Retrospective study conducted on the records of patients who were seen at Jordan University hospital in the period January 2016 to December 2020. All primigravid women with FBS that were done in early pregnancy before completed 20 weeks of gestation were included. Exclusion criteria were known diabetics, multiple pregnancies, thyroid dysfunction, patients taking steroids or any other medications for chronic illness (s) and those with missing data. Patients were divided into 2 groups; group had a FBS 80-120 mg/dl and group 2 with FBS less than 80 mg/dl. Pregnancy outcomes were then compared between the 2 groups.

Gestational age was confirmed by early ultra-sound (US) scan before 16 weeks gestation. All FBS samples were measured at our laboratory. Investigators collected data regarding patients' age, body mass index (BMI), FBS early in pregnancy, any complication in the pregnancy or the pregnancy outcome including miscarriage (defined as pregnancy loss before completed 24 weeks gestation), preterm delivery (defined as spontaneous vaginal delivery before completed 37 weeks gestation), gestational age at delivery, polyhydramnios, congenital abnormality (minor or major), stillbirth, intra-uterine fetal death (IUFD), neonatal death and mode of delivery. For those who underwent cesarean section, the indications were also identified. Fetal outcome included birth weight; APGAR score at 1 minute and APGAR score at 5 minutes. The APGAR score was determined by the neonatologists who routinely attend deliveries at our hospital.

Investigators also identified those who were diagnosed to have GDM with any intervention (metformin or insulin and their dosages). Diagnosis of GDM was based on a standard 75 gm glucose tolerance test (GTT) at 26-28 weeks gestation. A normal FBS level is lower than 95 mg/dL, one hour lower than 180 mg/dL, two hours lower than 155 mg/dL Three hours after drinking the glucose solution, a normal blood glucose level is lower than 140 mg/dL.

Eligibility Criteria:
Inclusion Criteria:

* Pregnant

Exclusion Criteria:

* Thyroid disorder
* Diabetes mellitus
* Taking Steroids
Study to Evaluate the Usability and Value of Integrated Digital Solutions in Medical Care of Participants With Multiple Sclerosis

The main purpose of this study is to assess the usability and value of the multiple sclerosis (MS) care management platform in terms of improved monitoring of people with MS (pwMS) in clinical practice.

This is a two-year prospective data collection study with additional data collection at baseline evaluating medical practice over a period of at least one year before the introduction of the MS care management platform.

The MS care management platform consists of:

A) icobrain ms, a cloud-based artificial intelligence (AI) solution to quantify brain volume and brain abnormalities and changes thereof on magnetic resonance imaging (MRI) scans and thereby providing insights into subclinical changes during disease progression in MS.

B) icompanion ms, which consists of i) A free participant mobile application (app) and website to keep track of participant reported health and medications and prepare participants for the next consultation.

ii) A web portal for healthcare professionals (HCPs), which is accessible via web browser. The MS care team will be able to access the participants' data entered via the participant app (active linking of systems by the participant required), as well as their participants' MRI images and icobrain ms volumetric brain reports automatically imported by the hospital picture archiving and communications system (PACS).

Eligibility Criteria:
Inclusion Criteria:

* Able to comply with the study protocol, including having a smartphone and being able and willing to access the icompanion ms patient app on a regular basis. To use all functionalities of the icompanion ms patient app, the user's smartphone must comply with the minimum system requirements (Android version 5.0 or above, iOS version 11 or above)
* Have a valid email address (for registration of icompanion ms)
* Have a definite diagnosis of RRMS
* Time since MS diagnosis ≥1 year
* Medical history recorded for at least 1 year before enrollment
* Expanded Disability Status Scale (EDSS) \<5.5

Exclusion Criteria:

* Any contra-indications to using icompanion ms patient app or website, as per the investigator's discretion
* Inability to complete an MRI
* Currently involved in an interventional trial
* Diagnosis of progressive MS (primary progressive multiple sclerosis \[PPMS\] or secondary progressive multiple sclerosis \[SPMS\])
Phase I Study of Sulfatinib(HMPL-012) in Patients With Advanced Solid Tumors

Sulfatinib (HMPL-012) is a novel oral small molecule that selectively inhibits vascular endothelial growth factor receptors (VEGFR) 1, 2, and 3 and inhibits FGFR kinase activity has demonstrated potent inhibitory effects on multiple human tumor xenografts. This first-in-human study is conducted to assess the maximum tolerated dose (MTD) and recommended dose for phase II ,to evaluate the pharmacokinetics , safety and preliminary anti-tumor activity of HMPL-012 at single doses and multiple doses .

This will be an open-label, phase I study. This study will evaluate the safety and pharmacokinetics of HMPL-012 after a single administration followed by a 28-Day continuous course of therapy; evaluate the safety and preliminary efficacy in an open-label administration of at the MTD. All subjects of this study will be permitted to continue therapy with only safety monitoring and monthly assessments for progression, if the product is well tolerated and the subject has stable disease or better

Eligibility Criteria:
Inclusion Criteria:

•≥ 18 and ≤ 70 years of age

* Histological or cytological confirmed solid malignant tumor
* ECOG performance status of 0-2
* Standard regimen failed or no standard regimen available
* Life expectancy of more than 12 weeks
* LVEF ≥ 50%

Exclusion Criteria:

* Pregnant or lactating women
* Adequate hepatic, renal, heart, and hematologic functions (platelets \<75 × 109/L, neutrophil \<1.5 × 109/L, hemoglobin \< 90g/dl ,serum creatinine within upper limit of normal(ULN), total bilirubin and serum transaminase within upper limit of normal(ULN), and PT, APTT, TT, Fbg normal
* Any factors that influence the usage of oral administration
* Evidence of uncontrolled CNS metastasis
* Intercurrence with one of the following: non-controlled hypertension, coronary artery disease, arrhythmia and heart failure
* Abuse of alcohol or drugs
* Less than 4 weeks from the last clinical trial
* Previous treatment with VEGF/VEGFR inhibition
* Disability of serious uncontrolled intercurrence infection
* Uncontrolled hemorrhage in GI
* Within 12 months before the first treatment occurs artery/venous thromboembolic events, such as cerebral vascular accident (including transient ischemic attack) etc.
* Within 6 months before the first treatment occurs acute myocardial infarction, acute coronary syndrome or CABG
* Bone fracture or wounds that was not cured for a long time
* Coagulation dysfunction, hemorrhagic tendency or receiving anticoagulant therapy
Predictors of Treatment Response to Aflibercept and Aqueous Cytokine Levels in Diabetic Macular Edema

Diabetic macular edema refers to swelling (fluid accumulation) in the center of the retina. The retina is like the film of a camera and is located in the back of the eye. This condition can develop in diabetics where swelling results from leaking of fluid from the blood vessels of the eye, into the center of the retina, the macula. If left untreated, this can affect central vision. The current standard treatment for diabetic macular edema includes medications injected directly into the eye (intravitreal injections) and laser eye treatment. The drugs that are injected directly into the eye are known as anti-Vascular Endothelial Growth Factor (anti-VEGF) agents which help to reduce the leaking. However, response in patients to these anti-VEGF drugs can vary and examination of predictive factors is required. This particular study examines cellular factors called cytokines in patients receiving aflibercept, a type of anti-VEGF drug, in the hopes of detecting changes in cytokines that can predict treatment response amongst groups of patients.


Eligibility Criteria:
Inclusion Criteria:

* Male or female aged 18 years or above
* Presence of Non Proliferative Diabetic Retinopathy (NPDR)
* Treatment Naïve patients with DME with central macular thickness of 310μm or more on SD-OCT (cirrus)
* Subjects with Type I or II diabetes mellitis
* Willing and able to provide informed consent for participation in the study

Exclusion Criteria:

* Proliferative diabetic retinopathy in the study eye or PRP within the last 12 months or anticipated PRP in the next 6 months
* Uncontrolled glaucoma
* History of intraocular surgery within 3 months in the study eye
* History of vitrectomy surgery
* Laser treatment within 3 months of study eye
* Vitreomacular traction, epiretinal membrane or any other maculopathy in the study eye
* Prior intravitreal injection within the past 6 months
* Known allergy to the study drug or fluorescein
* History of stroke or AMI within 6 months of enrollment
* Patients receiving dialysis for renal failure
* Patients currently on systemic immunosuppression
* Patients on two or more class of medication for glaucoma in study eye
* Patients with tuberculosis
* Patients who are pregnant.
* Unwilling or unable to follow or comply with all study related procedures
Recover L-PRP in Lateral Epicondylitis (REGP-11-00)

The objective of the study is to further characterize the performance of L-PRP prepared using the Biomet Recover Kit in the treatment of chronic LE. The study will explore the potential impact of patient demographics and baseline characteristics on treatment outcome. Furthermore it will track and document treatment effects, time course, and untoward effects following treatment of chronic LE with L-PRP from the Recover device. In addition, the utilization of healthcare resources and associated costs will be investigated in treated patients.

Clinical trials have been conducted to determine the efficacy and safety of Leukocyte- and Platelet-Rich Plasma (L-PRP) prepared with Biomet Recover L-PRP Mini Platelet Separation Kit for the treatment of tendinosis in a controlled setting. This study will allow for the capture and evaluation of real-world clinical data on a chronic LE patient population. The advantage of a post-market data collection is that it provides a way to examine clinical and patient reported outcomes along with the associated costs of chronic LE treatment in a diverse, clinically-relevant population. Although several registries exist which capture the outcomes following tendon/ligament reconstruction surgery, there are no known registries that capture outcomes following non-surgical treatment of chronic LE with Recover L-PRP. This study will fill that gap by allowing for an efficient data collection platform in a larger heterogeneous population of patients suffering from chronic LE and will document and more closely examine the treatment effects of Recover L-PRP.

Eligibility Criteria:
Inclusion Criteria:

1. Signed an independent ethics committee (IEC)-approved informed consent form (ICF).
2. Male or female of ≥ 18 years of age
3. Confirmed diagnosis of unilateral chronic LE
4. Duration of chronic LE symptoms ≥ 3 months
5. Failed at least one previous LE treatment (e.g. wait and see, physiotherapy, analgesics, NSAIDs, anti-inflammatory steroid injection and bracing, etc.).

   Exclusion Criteria:
6. No active systemic inflammatory condition (e.g., rheumatoid arthritis)
7. No active leukemia or metastatic malignant cells
8. No current chemotherapy treatments
9. No pregnancy
10. No lactation
11. No infected tendons, skin infection or skin disease in the area of the injection site.
12. Participating in another drug or device study.
TEAS for the Treatment of Pain in Bone Metastases of Lung Cancer

This multicenter, prospective, randomized controlled research study aims to objectively evaluate the role of transcutaneous electrical acupoint stimulation (TEAS), which combines the theory of acupuncture with transcutaneous electrical nerve stimulation (TENS) therapy, for the treatment of pain in patients with bone metastases from lung cancer.


Eligibility Criteria:
Inclusion Criteria:

* Fulfilled the diagnostic criteria of non-small cell lung cancer and had a diagnosis of definite bone-metastatic-related pain.
* Potent opioid analgesics have been prescribed regularly.
* Bone protective agents (bisphosphonates or desumumab) have been used regularly.
* Expected survival ≥ 3 months with no obvious contraindication to opioid therapy.
* Stable vital signs and ECOG-PS score ≤ 2 points; able to cooperate with researchers to complete relevant study evaluations.
* Signed informed consent.

Exclusion Criteria:

* Definitively diagnosed with pain unrelated to lung cancer.
* Received local radiation therapy or surgery targeting bone metastases within 1 week before enrollment or will receive during the intervention period. The surgery including vertebroplasty, radioparticle implantation, neurological lesions, and other minimally invasive interventions.
* Venous thrombosis in the upper and lower extremities (below the elbow / knee joint), active cerebrovascular disease, severe cardiopulmonary dysfunction, or those with respiratory depression.
* Pacemaker implantation or metallic implants in vivo.
* Skin lesions at the acupoints, poor skin condition, or other situations that are not suitable for treatment with TEAS.
* Opioid hypersensitivity.
* Psychiatric disorders or severe cognitive deficits.
* Participating in other clinical trialists influencing the evaluation of the results of this study.
Virtual Reality Mirror Therapy for Those With Acquired Brain Injury: A Clinical Pilot Study

The goal of this study is to investigate the effects of virtual reality based mirror therapy (VMT) on individuals with acquired brain injury when compared to a control group receiving traditional mirror therapy (TMT). This is a randomized controlled pilot study in which patients with hemiplegia will be assigned to VMT or TMT and the impact on upper extremity function will be observed.

The investigators are currently running a mirror therapy pilot project in the Hamilton Health Sciences Rehabilitation Program. Mirror therapy has been successfully used with people that have injuries such as strokes or other types of brain injuries that affect movement on one side of their body. Mirror therapy involves placing a mirror over the affected limb and angling it to reflect the unaffected limb. This creates a visual illusion that moving the unaffected limb also results in movement in the affected limb. This is theorized to aid recovery of the motor system in the brain. Virtual Reality (VR) can also be used with people with strokes and brain injuries and many studies of VR have shown positive results. In this study, the investigators will combine VR and mirror therapy. The investigators have designed a special new system that uses VR headset to make it appear that both limbs are moving when only the unaffected limb is moving. The investigators are going to do this by having people complete virtual tasks wearing this specially programmed headset. The tasks are everyday activities that a person might perform using two hands. Ultimately, the investigators hope to determine whether there is any difference between VR mirror therapy and regular mirror therapy in improving upper limb function.

Eligibility Criteria:
Inclusion Criteria:

* diagnosis of stroke or brain injury, including ischemic or hemorrhagic strokes, confirmed by radio logical evidence and evidence suggesting injury primarily to one side and exhibited by hemiplegia
* their post injury time is between 2 weeks and 2 years
* patients are between the age of 16 and 65 years old

Exclusion Criteria:

* greater than stage 4 on the CMSA
* behavioral impairments that may prevent safe or consistent participation
New Thyroid Fine Needle Aspiration Biopsy Apparatus

Evaluation of the effectivity of the new thyroid fine needle aspiration biopsy (FNAB) apparatus of which patented from Turkish Patent Institute.

The author group of this investigation produced a new thyroid fine needle aspiration biopsy (FNAB) apparatus and patented it from Turkish patent Institute. FNAB indicated nodular goitre patients are the subjects of this research. First, the investigators will perform standart FNAB after this procedure will perform FNAB with new apparatus. The investigators will evaluate the aspirates according to number of cells and malignity ratio of cells.

Eligibility Criteria:
Inclusion Criteria:

* fine needle aspiration biopsy indicated noduler goiter patients

Exclusion Criteria:

* diffuse goiter
Methylphenidate in Adults With Attention Deficit/Hyperactivity Disorder

Methylphenidate (MPH) is the first-line pharmacological treatment for adults with Attention-Deficit/Hyperactivity Disorder (ADHD). Nevertheless, there is considerable interindividual variability regarding the dose required, tolerability and response rates to MPH. The aim of this study is to address the clinical and genetic predictors of MPH treatment outcomes in ADHD.

Methylphenidate (MPH) is the most prescribed psychostimulant for children and adults with Attention-Deficit/Hyperactivity Disorder (ADHD). Meta-analyses and systematic reviews have shown that MPH is safe and efficacious in attenuating the core symptoms of ADHD, promoting overall clinical improvement. However, many patients still do not show an appropriate clinical response to the MPH treatment and there is considerable interindividual variability regarding the dose required, tolerability and response rates to MPH. Therefore, it is essential to address the clinical and genetic predictors of MPH treatment outcomes in ADHD.

Eligibility Criteria:
Inclusion Criteria:

* White Brazilian of European descent
* Fulfillment of the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, (DSM-IV) diagnostic criteria for ADHD
* Eligibility to immediate-release MPH (IR-MPH) treatment

Exclusion Criteria:

* Contraindication for IR-MPH use
* Current stimulant treatment
* Evidence of a clinically significant neurological disease that might affect cognition (e.g., delirium, dementia, epilepsy, head trauma, and multiple sclerosis)
* Current or past history of psychosis
* Estimated intelligence quotient score lower than 70